Dept. of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, David Geffen School of Medicine at UCLA, 1124 West Carson St., Torrance, CA 90502, USA.
Am J Physiol Lung Cell Mol Physiol. 2010 Nov;299(5):L672-80. doi: 10.1152/ajplung.00240.2010. Epub 2010 Aug 20.
The physiological development and homeostasis of the lung alveolus is determined by the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) by the interstitial lipofibroblast. We have recently shown (Dasgupta C et al., Am J Physiol Lung Cell Mol Physiol 296: L1031-L1041, 2009.) that PPAR-γ agonists administered postnatally accelerate lung maturation and prevent hyperoxia-induced lung injury. However, whether the same occurs antenatally is not known. The objective of this study was to test the hypothesis that the potent PPAR-γ agonist rosiglitazone (RGZ), administered antenatally, enhances fetal lung maturation and protects against hyperoxia-induced neonatal lung injury. Sprague-Dawley rat dams were administered either diluent or RGZ (3 mg/kg), at late gestation, to determine its effect on lung maturation and on hyperoxia (95% O(2) exposure for 24 h)-induced neonatal lung injury. The lungs were examined for the expression of specific markers of alveolar development (surfactant proteins A and B, cholinephosphate cytidylyltransferase-α, leptin receptor, triglyceride uptake, and [(3)H]choline incorporation into saturated phosphatidylcholine) and injury/repair, in particular, the markers of transforming growth factor-β signaling (activin receptor-like kinase-5, SMAD3, lymphoid enhancer factor-1, fibronectin, and calponin). Overall, antenatal RGZ accelerated lung maturation and blocked the inhibition of alveolar sacculation and septal wall thinning by hyperoxia. RGZ specifically stimulated the development of the alveolar epithelial type II cell, the lipofibroblast, and the vasculature. The increased expression of the transforming growth factor-β intermediates, such as SMAD3 and lymphoid enhancer factor-1, implicated in hyperoxic lung injury, was also blocked by antenatal RGZ treatment. In conclusion, PPAR-γ agonists can enhance fetal lung maturation and can effectively prevent hyperoxia-induced neonatal lung injury.
肺肺泡的生理发育和动态平衡由间质脂肪纤维母细胞中过氧化物酶体增殖物激活受体-γ(PPAR-γ)的表达决定。我们最近表明(Dasgupta C 等人,Am J Physiol Lung Cell Mol Physiol 296:L1031-L1041,2009.),出生后给予 PPAR-γ 激动剂可加速肺成熟并预防高氧诱导的肺损伤。然而,是否在产前也会发生这种情况尚不清楚。本研究的目的是检验以下假设:即给予产前强效的 PPAR-γ 激动剂罗格列酮(RGZ)可增强胎儿肺成熟并预防高氧诱导的新生儿肺损伤。在妊娠晚期,给予 Sprague-Dawley 大鼠母体给予稀释剂或 RGZ(3mg/kg),以确定其对肺成熟和高氧(95%O2 暴露 24 小时)诱导的新生儿肺损伤的影响。检查肺中肺泡发育的特定标志物(表面活性蛋白 A 和 B、磷酸胆碱胞苷转移酶-α、瘦素受体、甘油三酯摄取以及[3H]胆碱掺入饱和磷脂酰胆碱)和损伤/修复的表达,特别是转化生长因子-β信号通路的标志物(激活素受体样激酶-5、SMAD3、淋巴增强因子-1、纤维连接蛋白和钙调蛋白)。总的来说,产前 RGZ 加速了肺成熟,并阻止了高氧抑制肺泡囊泡化和间隔壁变薄。RGZ 特别刺激肺泡上皮 II 型细胞、脂肪纤维母细胞和血管的发育。与高氧性肺损伤相关的转化生长因子-β中间产物(如 SMAD3 和淋巴增强因子-1)的表达增加也被产前 RGZ 治疗所阻断。总之,PPAR-γ 激动剂可增强胎儿肺成熟,并能有效预防高氧诱导的新生儿肺损伤。